SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending as discussions revolve around its potential role in the Real World Asset (RWA) space, with some community members envisioning tokenized assets like houses being used as collateral on its blockchain. However, concerns persist regarding the project's revenue and financial sustainability, with some users pointing to its cashflow and governance as potential issues. Overall, there is much debate around the future of the project and its place in the evolving crypto landscape.

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token HMMM is trending as the community highlights its potential and notes its integration with Phantom Wallet. Social media buzz suggests growing interest and positive sentiment around HMMM, with many anticipating a potential breakout. Community members are using terms like "moon," "rocket," and "early entries" to describe their expectations for the token's performance.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Energy prices are in focus as XOM trends, with community members discussing potential breakouts and resistance levels. Bullish sentiment is fueled by news of production milestones in Guyana and a new deepwater deal, while some analysts are focused on XOM's cash flow and valuation. Discussions also include potential impacts from geopolitical events and the possibility of XOM returning to Russia.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as traders discuss its potential in the play-to-earn and virtual world sectors, focusing on its technology that bridges blockchain with gaming. Community members are weighing in on entry points and whether it's still early to invest, while also noting its recent listing on Robinhood and its ecosystem of AI agents. The conversation highlights the potential for significant growth, although some caution against pump-and-dump schemes.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible ($RARI) is trending as traders discuss its low market cap and potential for significant gains, especially if listed on more exchanges. Recent integration with Aleph Zero for NFT minting and trading is also generating buzz. Community members are actively speculating on possible price movements and anticipating a breakout.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXPI is trending as analysts update their ratings, with a focus on automotive and mobile sector growth potential. The community is discussing whether the stock is undervalued, while also noting the company's upcoming earnings call. Some are also pointing to the broader strength in semi chains.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending amid community discussions about potential Coinbase-related maintenance impacting trading. Some users are reporting order issues, while others highlight the token's low supply and potential for significant price movement. The coin's breakout from a descending triangle is being watched by traders.

Cadence Design Systems, Inc. engages in the provision of design and development of integrated circuits and electronic devices. It operates through the following geographical segments: Americas, Asia, EMEA, and Japan. The company was founded by Alberto Sangiovanni-Vincentelli, Gudmundur A. Hjartarson, K. Bobby Chao, and K. Charles Janac in June 1988 and is headquartered in San Jose, CA.

Cadence Design Systems, Inc.

Cadence Design Systems is trending as investors anticipate its upcoming earnings report, with community discussions focusing on AI tailwinds and the potential for another earnings beat. Despite some analysts lowering price targets, the stock maintains a generally positive outlook due to its strong position in chip design software and strategic initiatives. Options activity suggests significant movement is expected following the report.

Chevron Corp. engages in the provision of administrative, financial management, and technology support for energy and chemical operations. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as investors monitor rising geopolitical tensions and their potential impact on oil prices, particularly after reports of strikes in the Middle East. Community members are closely watching technical indicators and potential gap fills, while analysts weigh in on the company's long-term strategies, including expansion projects and cost-cutting initiatives. Some traders are seeing opportunity amidst volatility with the potential for call options to print.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

EDGE is trending as community members discuss its recent price movements and potential for further gains, particularly in relation to BTC's performance. Some investors are highlighting the token's fundamentals, potential catalysts, and possible links to Coinbase, while others are closely watching for breakout opportunities and key resistance levels. The community is also weighing in on its trading platform and potential Binance listing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=761347961&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>,&nbsp;a provider of ETFs designed for sophisticated investors and professional traders, today launched nine new single stock leveraged ETFs, seven of which are first-to-market strategies. The funds, all listed on Cboe, seek to deliver twice (200%) the daily performance of a specific underlying stock.The following ETFs are first-to-market exposures:<ul><li>Tradr 2X Long BLSH Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=3130326393&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fblsx&amp;a=BLSX">BLSX</a>) – tracks Bullish Limited (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">BLSH</a>)</li><li>Tradr 2X Long DASH Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=2869777778&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fdasx&amp;a=DASX">DASX</a>) – tracks DoorDash, Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">DASH</a>)</li><li>Tradr 2X Long FLY Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=988935304&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fflyt&amp;a=FLYT">FLYT</a>) – tracks Firefly Aerospace, Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">FLY</a>)</li><li>Tradr 2X Long NEM Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=383478146&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fnwmx&amp;a=NWMX">NWMX</a>) – tracks Newmont Corporation (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">NEM</a>)</li><li>Tradr 2X Long OPEN Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=4123964757&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fopex&amp;a=OPEX">OPEX</a>) – tracks Opendoor Technologies Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">OPEN</a>)</li><li>Tradr 2X Long SRPT Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=2743176005&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fsrpu&amp;a=SRPU">SRPU</a>) – tracks Sarepta Therapeutics, Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">SRPT</a>)</li><li>Tradr 2X Long WULF Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=1776551262&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fwulx&amp;a=WULX">WULX</a>) – tracks TeraWulf, Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">WULF</a>)</li></ul>Today's launch also includes the following ETFs:<ul><li>Tradr 2X Long IREN Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=2078107318&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Firex&amp;a=IREX">IREX</a>) – tracks IREN Limited (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">IREN</a>)</li><li>Tradr 2X Long QS Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=3975677157&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fqsx&amp;a=QSX">QSX</a>) – tracks QuantumScape Corporation (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-debuts-leveraged-etfs-on-blsh-dash-fly-iren-nem-open-qs-srpt--wulf-302591439.html#financial-modal">QS</a>)</li></ul>"This is our largest set of single-stock ETF launches to date and covers several trailblazing stories across a swath of industries," said Matt Markiewicz, Head of Product and Capital Markets at Tradr ETFs. "In addition to electrifying AI-infrastructure plays like IREN and TeraWulf, we are introducing the industry's first single-stock ETF on a gold miner represented by Newmont, the world's largest gold company."In 2022, Tradr ETFs became the first issuer to launch leveraged ETFs on single stocks, starting with TSLQ for Tesla and NVDS for Nvidia. With today's listings, Tradr's lineup has grown to 48 leveraged ETFs representing over $2 billion in assets under management. Tradr's strategies can be accessed through most brokerage platforms and allow investors to avoid the hassle of using margin and the complexity of options trading. The firm continues its mission of providing sophisticated investors with innovative trading tools that enhance their ability to express market views with precision and efficiency.For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=2678754280&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=761347961&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a>&nbsp;are designed for sophisticated investors and professional traders&nbsp;who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4538115-1&amp;h=2678754280&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a> . The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000768SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Funds seek to provide 200% long exposure on a variety of industry leaders

Others

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF PR Newswire NEW YORK, Oct. 23, 2025...

Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF PR Newswire NEW YORK, Oct. 21...

Shares of Sarepta Therapeutics rose nearly 5% in early premarket trading on Wednesday as the company prepared to present new findings at the 30th Annual World Muscle Society Congress (WMS 2025) in Vienna, Austria.On Wednesday, the company will present new results from its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy (DMD), including updated safety data and evidence of micro-dystrophin protein production in children as young as three who received the treatment in the ENDEAVOR and ENVOL studies.&nbsp;The company will also share findings from a real-world study tracking lung function in boys and young men with advanced stages of Duchenne treated with casimersen, as well as pooled three-year functional outcomes comparing gene therapy recipients with external control groups.Independent research teams will also present complementary data on delandistrogene moxeparvovec, including one-year motor function results in young patients and early findings on the use of sirolimus to help reduce the risk of liver injury in people receiving AAV-based gene therapy.Later in the week, Sarepta plans to unveil results from the Phase 3 EMERGENE study evaluating bidridistrogene xeboparvovec in patients with limb-girdle muscular dystrophy type 2E/R4, alongside late-breaking data on gene expression and safety.Sarepta’s gene therapy Elevidys (delandistrogene moxeparvovec-rokl), the first and only FDA-approved treatment designed to restore dystrophin production in muscle tissue for people with Duchenne muscular dystrophy, remains under close scrutiny following recent safety concerns. The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-pauses-elevidys-shipments-amid-fda-label-review/ch8MbFbR5rD">temporarily paused shipments</a> earlier this year after reporting two patient deaths from liver failure linked to treatment.In July, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-bernstein-barclays-about-sarepta-elevidys/choaPoVR5yF">FDA cleared Sarepta to resume shipments of Elevidys</a> for children who can still walk, while maintaining a pause for those who can no longer walk, as discussions continue regarding updated safety labeling.&nbsp;On Stocktwits, retail sentiment for Sarepta was ‘extremely bullish’ amid ‘high’ message volume.One user suggested growing optimism around Sarepta’s upcoming updates, stating that traders appear to be anticipating strong data followed by solid financial results, adding that short sellers “can’t hold it back any longer.”<stembedurl>https://stocktwits.com/Plowmaster/message/631424297</stembedurl>Another user speculated that a takeover could be on the table, calling an “$80 sale possible,” amid renewed momentum in global mergers and acquisitions driven by expectations of rate cuts.<stembedurl>https://stocktwits.com/MissionImpossibl/message/631420179</stembedurl><a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> has declined 81% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket

Investors turned upbeat ahead of Sarepta’s data presentations in Vienna, where the company is expected to share new Duchenne muscular dystrophy results and updates from its broader gene therapy pipeline.

Equity

Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure about $700 million of debt.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-refinancing-approximately-700">said</a> it will exchange approximately $700 million in aggregate principal amount of its existing convertible notes due 2027 for roughly $602 million in new 4.875% convertible senior notes due 2030, up to approximately 6.7 million shares of its common stock, and about $123.3 million in cash.Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to investors. A fear of a potential dilution appears to have disappointed investors. SRPT stock was down over 7% at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. The stock is among the top ten trending names on the platform.<figure class="image"><img style="aspect-ratio:569/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_10_26_20_AM_png_8591ecfd20.webp" alt="Screenshot 2025-08-21 at 10.26.20 AM.png" width="569" height="62"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the refinancing.<stembedurl>https://stocktwits.com/scaredmoneymakenomoney/message/626069691</stembedurl>CEO Doug Ingram said that the exchange marks an important progress in the company’s long-term financial strategy. "By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction that significantly enhances our balance sheet flexibility and strengthens our financial position,” Ingram said.Ingram also said that the company believes it is well-positioned to fully fund its pipeline and meet its near-term obligations.Bank of America said that the debt refinancing transaction "makes sense" as it helps mitigate some near-term concerns about the company's ability to meet its obligations. Still, the firm continues to think clarity on uptake of Elevidys from here will be needed to get more comfortable with the long-term outlook.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals. Citi on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/citi-believes-fda-may-closely-watch-sarepta-safeguards-for-gene-therapy-in-non-ambulatory-dmd-patients/chsiUM2RdLP">said</a> that the U.S. Food and Drug Administration may take a “more comprehensive look” at the regimen devised by Sarepta for non-ambulatory patients.Last month, the company said that it had initiated immediate changes to reduce operating expenses, including a 36% workforce reduction and pipeline reprioritization, in a bid to meet its 2027 financial obligations.Following the crisis with the gene therapy, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/analyst-says-sarepta-lost-credibility-by-exiting-arrowhead-at-a-loss/chsRn7vRdON">unwound</a> its equity position in Arrowhead Pharmaceuticals earlier this month, in less than a year of its investment.SRPT stock is down by 84% this year and by about 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-to-invest-2-billion-to-expand-manufacturing-in-north-carolina/chsSyKYRdig">This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of immunomodulation required for Sarepta Therapeutics' gene therapy (SRPT) Elevidys.The FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy (DMD) patients on Elevidys, Citi said, as per TheFly. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.Citi has a ‘Sell’ rating and a $14 price target on <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> shares. On Stocktwits, retail sentiment around Sarepta fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:563/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_2_11_08_PM_png_5b28899976.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>Citi made the observations in light of the FDA’s recommendations for Rocket Pharmaceuticals (RCKT) made public earlier in the day.Rocket <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> earlier on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said.The agency allowed the trial to resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing and with an immunomodulatory regimen more closely reflecting the one administered in an early-stage study pediatric cohort.Sarepta, like Rocket Pharma, has been plagued by patient deaths. It's gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.SRPT stock is down by 83% this year and by about 86% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky...

H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its credibility in capital allocation.The firm also highlighted concerns that Sarepta's late-stage and commercial portfolio may not generate sufficient near-term cash to support its current debt and pipeline ambitions.H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. The brokerage noted that <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> fully unwound its equity position in Arrowhead less than a year after investing $325 million in the stock. The unwinding represented a 31% decline as compared to the purchase price, it added.On Stocktwits, retail sentiment around the stock trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Retail chatter around the stock jumped 131% over the past 24 hours, as of Thursday morning.<figure class="image"><img style="aspect-ratio:625/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_11_12_15_AM_png_aaca6c7ce4.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="625" height="58"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Sarepta selling its investment in Arrowhead.<stembedurl>https://stocktwits.com/Zergg/message/625149352</stembedurl>Another user hopes the stock will hit $30 by next week.<stembedurl>https://stocktwits.com/markxtill/message/625143002</stembedurl>Sarepta on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-keeps-retail-traders-bullish-as-stock-surges-on-100-m-milestone-payment-to-arrowhead-in-genetic-disorder-trial/chsR9ZARdak">said</a> that it sold about 9.27 million shares of common stock of Arrowhead in a privately negotiated block trade from which it expects to receive at least $174 million in gross proceeds.The company also said that it has entered into an agreement with Arrowhead under which it will transfer over 2.66 million shares of <a href="https://stocktwits.com/symbol/ARWR">Arrowhead</a> back to the company to satisfy a $50 commitment of a $100 milestone payment obligation. The remaining $50 million will be received in cash, Arrowhead said. Sarepta previously owned 11.93 million shares of Arrowhead stock.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure. Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.However, SRPT stock is down by 84% this year and by 85% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hertz-expands-program-allowing-prolonged-3-day-test-drives-before-vehicle-purchase-to-over-100-cities/chsRlcNRdOh">Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Sarepta Sells Arrowhead Stake to Fund Milestone Payment

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Shares of Sarepta Therapeutics hit their highest level in nearly a month on Wednesday after the company said a safety review and enrollment progress in its Phase 1/2 trial of SRP-1003 for type 1 myotonic dystrophy (DM1) triggered a $100 million milestone payment to Arrowhead Pharmaceuticals.<a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> jumped 8.5% to close at $20.4 on Wednesday, with an additional 1.6% gain in after-hours trading.The payment was triggered after Arrowhead reached the first of two predetermined enrollment targets in the study, following a review of the safety data.&nbsp;SRP-1003 is an experimental RNA interference therapy being developed for type 1 myotonic dystrophy.To help fund the milestone payment, Sarepta sold 9.3 million shares of Arrowhead in a privately negotiated block trade, generating at least $174 million in gross proceeds.&nbsp;Arrowhead will also redeem 2.7 million shares from Sarepta for $50 million, prefunding half of the milestone obligation.The company plans to share early results from the SRP-1003 trial and its facioscapulohumeral muscular dystrophy (FSHD) program in the second half of 2025.On Stocktwits, retail sentiment was ‘bullish’ for Sarepta Therapeutics and ‘extremely bullish’ for Arrowhead Pharmaceuticals, with 24-hour message volumes surging 872% and 122%, respectively.One user remarked that upgrades for Sarepta Therapeutics keep coming, adding that the market may be underestimating how quickly sentiment can shift when major investors get involved.&nbsp;<stembedurl>https://stocktwits.com/BookerB/message/625098239</stembedurl>Another said the stock could still rise tenfold within a year if European approval comes through and with multiple trials underway, calling it a bargain and urging others to buy before the current discount disappears.<stembedurl>https://stocktwits.com/Mejeko/message/625096804</stembedurl>While Sarepta’s stock has declined 83.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/ARWR">Arrowhead’s stock</a> gained 6.3% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$19.97
Beta	0.91
Avg. Volume	5.91M
PE Ratio	-30.07

52-Week High	$138.81
52-Week Low	$10.42
Market Capitalization	$2.23B
EPS (Annual)	$2.34
Price to Book	1.64
Revenue Per Employee	$1.39M
Enterprise Value/EBITDA	N/A

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc